80.00
前日終値:
$75.80
開ける:
$81.5
24時間の取引高:
15.66M
Relative Volume:
3.55
時価総額:
$46.93B
収益:
$5.69B
当期純損益:
$4.15B
株価収益率:
11.51
EPS:
6.95
ネットキャッシュフロー:
$623.10M
1週間 パフォーマンス:
+4.59%
1か月 パフォーマンス:
+3.94%
6か月 パフォーマンス:
+15.96%
1年 パフォーマンス:
+34.00%
Edwards Lifesciences Corp Stock (EW) Company Profile
名前
Edwards Lifesciences Corp
セクター
電話
(949) 250-2500
住所
ONE EDWARDS WAY, IRVINE, CA
EW を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
EW
Edwards Lifesciences Corp
|
80.00 | 44.46B | 5.69B | 4.15B | 623.10M | 6.95 |
![]()
ABT
Abbott Laboratories
|
126.54 | 218.59B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
106.14 | 157.13B | 18.49B | 2.51B | 2.72B | 1.68 |
![]()
SYK
Stryker Corp
|
403.53 | 151.59B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
92.94 | 118.29B | 33.54B | 4.66B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-24 | アップグレード | Piper Sandler | Neutral → Overweight |
2025-01-30 | アップグレード | Stifel | Hold → Buy |
2025-01-16 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
2024-12-16 | アップグレード | BofA Securities | Neutral → Buy |
2024-10-11 | 再開されました | Morgan Stanley | Equal-Weight |
2024-09-18 | ダウングレード | Jefferies | Buy → Hold |
2024-07-31 | アップグレード | Daiwa Securities | Neutral → Outperform |
2024-07-29 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2024-07-25 | ダウングレード | BofA Securities | Buy → Neutral |
2024-07-25 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-07-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-07-25 | ダウングレード | TD Cowen | Buy → Hold |
2024-07-25 | ダウングレード | Truist | Buy → Hold |
2024-05-30 | 開始されました | Goldman | Buy |
2024-05-22 | アップグレード | Citigroup | Neutral → Buy |
2024-05-14 | アップグレード | Deutsche Bank | Hold → Buy |
2024-03-07 | アップグレード | BofA Securities | Neutral → Buy |
2024-02-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
2023-12-11 | ダウングレード | Citigroup | Buy → Neutral |
2023-11-28 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
2023-09-26 | アップグレード | Oppenheimer | Perform → Outperform |
2023-07-19 | 開始されました | Robert W. Baird | Outperform |
2023-05-30 | 再開されました | Morgan Stanley | Overweight |
2023-03-29 | 開始されました | UBS | Neutral |
2023-03-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2023-02-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2023-01-31 | ダウングレード | Bernstein | Outperform → Underperform |
2023-01-30 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-12-06 | ダウングレード | Stifel | Buy → Hold |
2022-10-28 | ダウングレード | Oppenheimer | Outperform → Perform |
2022-10-26 | 開始されました | Mizuho | Buy |
2022-10-18 | 開始されました | Barclays | Overweight |
2022-10-12 | 開始されました | Jefferies | Buy |
2022-07-29 | ダウングレード | Canaccord Genuity | Buy → Hold |
2022-04-13 | 開始されました | Truist | Buy |
2022-04-06 | 開始されました | Wolfe Research | Outperform |
2022-03-16 | アップグレード | Bernstein | Mkt Perform → Outperform |
2022-03-02 | 再開されました | BofA Securities | Neutral |
2022-02-02 | アップグレード | UBS | Neutral → Buy |
2022-01-27 | 繰り返されました | Citigroup | Buy |
2022-01-27 | 繰り返されました | Evercore ISI | Outperform |
2022-01-27 | 繰り返されました | Raymond James | Outperform |
2022-01-27 | 繰り返されました | Stifel | Buy |
2022-01-27 | 繰り返されました | UBS | Neutral |
2021-12-17 | アップグレード | JP Morgan | Neutral → Overweight |
2021-12-15 | アップグレード | Citigroup | Neutral → Buy |
2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
2021-12-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2021-07-30 | 繰り返されました | Canaccord Genuity | Buy |
2021-07-30 | 繰り返されました | Deutsche Bank | Hold |
2021-07-30 | 繰り返されました | Jefferies | Buy |
2021-07-30 | 繰り返されました | Morgan Stanley | Overweight |
2021-07-30 | 繰り返されました | Oppenheimer | Outperform |
2021-07-30 | 繰り返されました | Stifel | Buy |
2021-07-30 | 繰り返されました | UBS | Neutral |
2021-07-30 | 繰り返されました | Wells Fargo | Equal Weight |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-15 | 開始されました | Atlantic Equities | Neutral |
2021-04-05 | アップグレード | Evercore ISI | In-line → Outperform |
2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
2020-12-11 | 繰り返されました | Canaccord Genuity | Buy |
2020-09-11 | 開始されました | Wolfe Research | Underperform |
2020-04-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2020-03-05 | 開始されました | Citigroup | Buy |
2020-02-13 | 開始されました | Goldman | Neutral |
2020-02-06 | 再開されました | BTIG Research | Neutral |
2020-01-10 | 開始されました | Oppenheimer | Outperform |
2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
2019-10-24 | 繰り返されました | Canaccord Genuity | Buy |
2019-09-23 | 開始されました | Piper Jaffray | Overweight |
2019-07-24 | 繰り返されました | BofA/Merrill | Buy |
2019-03-18 | 繰り返されました | Canaccord Genuity | Buy |
2019-01-18 | アップグレード | BofA/Merrill | Neutral → Buy |
2019-01-03 | 開始されました | Deutsche Bank | Hold |
2018-11-28 | 開始されました | UBS | Neutral |
2018-10-16 | 開始されました | Barclays | Underweight |
2018-10-02 | ダウングレード | BofA/Merrill | Buy → Neutral |
2018-10-02 | ダウングレード | Guggenheim | Buy → Neutral |
すべてを表示
Edwards Lifesciences Corp (EW) 最新ニュース
Edwards Lifesciences Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Edwards Lifesciences stock price target raised to $84 from $75 at TD Cowen - Investing.com
Edwards Lifesciences stock price target raised to $89 at RBC on growth outlook - Investing.com
Edwards Lifesciences (EW) Target Price Raised by JP Morgan | EW Stock News - GuruFocus
Edwards Lifesciences sales up nearly 12% in Q2 - MassDevice
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corporation Stock Analysis and ForecastPhenomenal returns - PrintWeekIndia
Edwards Lifesciences Q2 EarningsEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Exec Larry Wood Departs for Procept BioRobotics - Orange County Business Journal
Edwards Lifesciences (EW) Target Price Raised by Baird Analyst | - GuruFocus
Edwards Lifesciences’ MITRIS Valve Study: A Key Development for Investors - TipRanks
Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results - Benzinga
Edwards Lifesciences (EW) Surpasses Earnings and Revenue Expecta - GuruFocus
Edwards Lifesciences Q2 2025 Earnings Report - MarketBeat
Edwards Lifesciences stock reaches 52-week high at 81.86 USD - Investing.com
Edwards Lifesciences (EW) Receives Price Target Upgrade from Deutsche Bank | EW Stock News - GuruFocus
Edwards Lifesciences (EW) Receives Price Target Boost from Baird | EW Stock News - GuruFocus
JPMorgan Adjusts Edwards Lifesciences (EW) Price Target Following Strong Q2 Results | EW Stock News - GuruFocus
Edwards loses longtime TAVR leader Larry Wood - Yahoo Finance
Edwards Lifesciences Corp (EW) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Raised ... - Yahoo Finance
Edwards Lifesciences Corp (EW) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Raised ... By GuruFocus - Investing.com Canada
Edwards Lifesciences Corp (EW) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Raised Guidance - GuruFocus
Edwards Lifesciences Reports Strong Q2 Growth - TipRanks
Earnings call transcript: Edwards Lifesciences Q2 2025 beats forecasts, stock dips By Investing.com - Investing.com South Africa
Edwards Lifesciences (EW) Surges After Earnings Report | EW Stock News - GuruFocus
Compared to Estimates, Edwards Lifesciences (EW) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO - GlobeNewswire Inc.
After-hours movers: Edwards Lifesciences, Intel, Deckers Brands and more - Investing.com
Edwards Lifesciences Corp Reports Q2 Revenue of $1.53 Billion, E - GuruFocus
Edwards Lifesciences shares leap 7% on strong Q2 results, sales growth guidance - Investing.com
Edwards Lifesciences Corp. Reports Retreat In Q2 Income - Nasdaq
Edwards Lifesciences earnings beat by $0.05, revenue topped estimates - Investing.com
Edwards Lifesciences Reports Second Quarter Results - Yahoo Finance
Edwards recalls certain arterial cannula devices - MassDevice
Edwards Lifesciences (EW) Awaits Key Earnings Report | EW Stock News - GuruFocus
EDWARDS LIFESCIENCES Earnings Preview: Recent $EW Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Edwards Lifesciences Corp expected to post earnings of 62 cents a shareEarnings Preview - TradingView
Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings - The Globe and Mail
Heart Valve Devices Market is projected to grow US$ 34.6 billion - openPR.com
Curious about Edwards Lifesciences (EW) Q2 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Earnings Preview: What To Expect From Edwards Lifesciences' Report - MSN
Lobbying Update: $360,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed - Quiver Quantitative
Edwards Lifesciences to Announce Q2 2025 Results, Driving Growth in Structural Heart Innovations - AInvest
What drives Edwards Lifesciences Corporation stock priceHigh-yield growth strategies - jammulinksnews.com
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025 - Yahoo Finance
Morgan Stanley Adjusts Price Target on Edwards Lifesciences to $81 From $75, Maintains Equalweight Rating - MarketScreener
Edwards Lifesciences Seeks to Add to its Irvine Campus - Orange County Business Journal
Edwards Lifesciences’ PROGRESS Trial: A Game-Changer for Aortic Stenosis Treatment? - TipRanks
Edwards Lifesciences Launches MITRIS Valve Study in China: A Potential Market Game-Changer - TipRanks
Argus Initiates Edwards Lifesciences at Buy, $90 Price Target - MarketScreener
Edwards Lifesciences’ SAPIEN X4 Valve Study: A Potential Game-Changer in Heart Valve Treatment - TipRanks
Edwards Lifesciences Corp (EW) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):